DAVID OGAMI: Open Payments
NPI 1699841809 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$943 in 23 payments from 4 companies in 2025. Trend: 2023 $616 · 2024 $895 · 2025 $943
Food & beverage: $943
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 14 | $547 |
| E.R. Squibb & Sons, L.L.C. | 3 | $225 |
| Alkermes, Inc. | 3 | $90 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $81 |
Products named: INGREZZA, COBENFY, ARISTADA, CAPLYTA.
Industry payments across CA — which companies pay providers there.
